NASDAQ:SNSE Sensei Biotherapeutics (SNSE) Stock Price, News & Analysis → Move Your Money Before May 22 (From Stansberry Research) (Ad) Free SNSE Stock Alerts $1.02 +0.02 (+1.99%) (As of 04:28 PM ET) Add Compare Share Share Today's Range$1.00▼$1.0450-Day Range$0.76▼$1.1752-Week Range$0.51▼$1.72Volume6,104 shsAverage Volume63,970 shsMarket Capitalization$25.57 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Sensei Biotherapeutics alerts: Email Address Sensei Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside292.2% Upside$4.00 Price TargetShort InterestHealthy0.50% of Float Sold ShortDividend StrengthN/ASustainability-0.38Upright™ Environmental ScoreNews Sentiment0.33Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.97) to ($0.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.60 out of 5 starsMedical Sector119th out of 908 stocksPharmaceutical Preparations Industry40th out of 424 stocks 3.5 Analyst's Opinion Consensus RatingSensei Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSensei Biotherapeutics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.50% of the float of Sensei Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverSensei Biotherapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sensei Biotherapeutics has recently decreased by 48.14%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSensei Biotherapeutics does not currently pay a dividend.Dividend GrowthSensei Biotherapeutics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSensei Biotherapeutics has received a 77.43% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Basic medical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Sensei Biotherapeutics is -0.38. Previous Next 1.9 News and Social Media Coverage News SentimentSensei Biotherapeutics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Sensei Biotherapeutics this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added Sensei Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sensei Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders25.50% of the stock of Sensei Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 10.50% of the stock of Sensei Biotherapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Sensei Biotherapeutics are expected to grow in the coming year, from ($0.97) to ($0.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sensei Biotherapeutics is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sensei Biotherapeutics is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSensei Biotherapeutics has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Sensei Biotherapeutics Stock (NASDAQ:SNSE)Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.Read More SNSE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNSE Stock News HeadlinesApril 24, 2024 | globenewswire.comSensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual MeetingApril 23, 2024 | americanbankingnews.comHead-To-Head Contrast: Propanc Biopharma (OTCMKTS:PPCB) versus Sensei Biotherapeutics (NASDAQ:SNSE)April 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 9, 2024 | globenewswire.comSensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual ConferenceApril 4, 2024 | uk.investing.comSensei Biotherapeutics CFO Erin Colgan to resignApril 4, 2024 | globenewswire.comSensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor MicroenvironmentMarch 22, 2024 | globenewswire.comSensei Biotherapeutics to Participate in the 3rd Annual VISTA SymposiumMarch 6, 2024 | globenewswire.comSensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific ConferencesApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.February 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Sensei Biotherapeutics on Strong Fiscal Health and Promising Clinical TrialsFebruary 28, 2024 | globenewswire.comSensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business HighlightsFebruary 9, 2024 | msn.comSensei Biotherapeutics Announces Board Member Resignation and Consultant RoleFebruary 9, 2024 | msn.comSensei Biotherapeutics Streamlines Board, Appoints Interim ChairFebruary 7, 2024 | finance.yahoo.comSensei Biotherapeutics to Present at Upcoming ConferencesJanuary 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Sensei Biotherapeutics Amidst Promising SNS-101 Clinical Progress and Favorable Safety DataJanuary 4, 2024 | finance.yahoo.comSensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming MilestonesDecember 4, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Praxis Precision Medicines (PRAX) and Sensei Biotherapeutics (SNSE)December 4, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of Sensei Biotherapeutics (SNSE) with Buy RecommendationNovember 7, 2023 | msn.comSensei Biotherapeutics GAAP EPS of -$0.28 in-lineNovember 7, 2023 | finance.yahoo.comSensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNovember 7, 2023 | finance.yahoo.comSensei Biotherapeutics Inc (SNSE) Reports Q3 2023 Financial ResultsNovember 3, 2023 | finance.yahoo.comSensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual MeetingOctober 25, 2023 | finance.yahoo.comSensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual MeetingOctober 24, 2023 | bizjournals.comRockville cancer therapy firm Sensei Biotherapeutics faces delisting threat from NasdaqOctober 23, 2023 | finance.yahoo.comSensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023September 27, 2023 | finance.yahoo.comSensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®September 21, 2023 | finance.yahoo.comSensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy ConferenceSee More Headlines Receive SNSE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sensei Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/26/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SNSE CUSIPN/A CIK1829802 Webwww.senseibio.com Phone240-243-8000FaxN/AEmployees28Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+284.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-34,100,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-44.01% Return on Assets-38.58% Debt Debt-to-Equity Ratio0.01 Current Ratio11.92 Quick Ratio11.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.60 per share Price / Book0.40Miscellaneous Outstanding Shares25,070,000Free Float18,678,000Market Cap$26.07 million OptionableNot Optionable Beta0.17 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. John K. Celebi M.B.A. (Age 52)President, CEO & Director Comp: $799.69kDr. Edward Van der Horst Ph.D. (Age 51)Chief Scientific Officer Comp: $444.87kMs. Lora PikeVice President of Investor Relations & CommunicationsMr. Christopher W. Gerry J.D.Senior VP, General Counsel & SecretaryMs. Stephanie Krebs M.B.A.M.S., Chief Business OfficerDr. Aaron Weitzman FACPM.D., Ph.D., Chief Medical OfficerMore ExecutivesKey CompetitorsUnity BiotechnologyNASDAQ:UBXVaxxinityNASDAQ:VAXXEnlivex TherapeuticsNASDAQ:ENLVLipocineNASDAQ:LPCNEyenoviaNASDAQ:EYENView All CompetitorsInsidersJohn CelebiBought 500 shares on 9/11/2023Total: $425.00 ($0.85/share)Apeiron Investment Group Ltd.Sold 3,441,661 sharesTotal: $5.44 M ($1.58/share)View All Insider Transactions SNSE Stock Analysis - Frequently Asked Questions Should I buy or sell Sensei Biotherapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sensei Biotherapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SNSE shares. View SNSE analyst ratings or view top-rated stocks. What is Sensei Biotherapeutics' stock price target for 2024? 1 Wall Street analysts have issued 12-month target prices for Sensei Biotherapeutics' shares. Their SNSE share price targets range from $4.00 to $4.00. On average, they predict the company's share price to reach $4.00 in the next year. This suggests a possible upside of 292.2% from the stock's current price. View analysts price targets for SNSE or view top-rated stocks among Wall Street analysts. How have SNSE shares performed in 2024? Sensei Biotherapeutics' stock was trading at $0.6920 on January 1st, 2024. Since then, SNSE shares have increased by 47.4% and is now trading at $1.02. View the best growth stocks for 2024 here. Are investors shorting Sensei Biotherapeutics? Sensei Biotherapeutics saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 81,000 shares, a decrease of 48.1% from the March 31st total of 156,200 shares. Based on an average daily volume of 69,200 shares, the short-interest ratio is currently 1.2 days. Approximately 0.5% of the company's shares are sold short. View Sensei Biotherapeutics' Short Interest. When is Sensei Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our SNSE earnings forecast. How were Sensei Biotherapeutics' earnings last quarter? Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) released its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.02. When did Sensei Biotherapeutics IPO? Sensei Biotherapeutics (SNSE) raised $100 million in an IPO on Friday, February 5th 2021. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Citigroup, Piper Sandler, Berenberg and Oppenheimer & Co. served as the underwriters for the IPO. How do I buy shares of Sensei Biotherapeutics? Shares of SNSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SNSE) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sensei Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
